Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
The trouble with TIGITs: How 'overenthusiasm' led to Big Pharma's risky $6B gamble
biotech deals
Biotech
Seyltx gains option to boost cough pipeline with 8 NeurOp drugs
Cough-focused biotech Seyltx has secured the option to license a portfolio of eight GluN2B antagonists from NeurOp.
James Waldron
Jun 5, 2025 10:40am
Biogen blueprints $1B CNS deal with RNAi biotech
May 27, 2025 10:55am
Juri inks $210M T-cell engager deal with China biotech
May 27, 2025 6:00am
Genentech sticks 2nd molecular glue deal with Orionis worth $2B
May 21, 2025 8:30am
Revised Blueprint-VantAI deal turns focus to molecular glues
May 20, 2025 10:32am
AbbVie tosses ADARx $335M for siRNA options deal
May 14, 2025 9:00am
